IDBI Healthcare Growth Direct Plan
SIP amount
Temporarily restricted by fund house
Lumpsum amount
Temporarily restricted by fund house

IDBI Healthcare Growth Direct Plan

NAV
₹31.5304
+0.38%
(21 Nov)
AUM
81 Cr
TER
1.21%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+51.5%
+49.4%
+44.9%
+43.3%
+42.4%
3Y
+34.5%
+32.3%
+17.4%
+33.8%
+31.8%
5Y
+24.7%
+27.9%
+24.2%
NA
+30.5%
ALL
+12.4%
+17.6%
+22.2%
+28.7%
+17.9%
VOL
20.3%
19.6%
15.9%
22.7%
18.2%
TER
0.8%
0.8%
1.2%
0.5%
1.2%
AUM
₹4,471 Cr
₹1,331 Cr
₹81 Cr
₹5,456 Cr
₹6,779 Cr
INFO
0.61
0.90
1.40
1.26
0.98
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
IDBI Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Aug
Top holdings
Sun Pharmaceuticals Industries Ltd
11.3%
Piramal Pharma Ltd
6.7%
Artemis Medicare Services Ltd Ordinary Shares
6.4%
Torrent Pharmaceuticals Ltd
6.0%
Glenmark Pharmaceuticals Ltd
5.6%
Cipla Ltd
5.3%
Mankind Pharma Ltd
4.9%
J.B. Chemicals & Pharmaceuticals Ltd
4.5%
Abbott India Ltd
4.3%
Alkem Laboratories Ltd
4.2%
Top industry exposure
Healthcare
93.1%
Basic Materials
3.4%
Other information
Minimum SIP
Restricted (AMC)
Minimum lumpsum
Restricted (AMC)
Additional lumpsum
Restricted (AMC)
Portfolio turnover
40%
Lock-in period
-
Exit load
• 1% for redemption within 90 days
Fund objective
The objective of the Scheme is to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. However there can be no assurance that the investment objective under the scheme will be realized.
Fund manager(s)
Karan Doshi

FAQs